NDAORALPELLETSPriority Review
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
HCV NS3/4A Protease Inhibitors
Pharmacologic Class:
Hepatitis C Virus NS3/4A Protease Inhibitor
Clinical Trials (1)
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Started Feb 2017
10 enrolled
Chronic Kidney DiseaseChronic Hepatitis C
Loss of Exclusivity
LOE Date
Dec 5, 2035
118 months away
Patent Expiry
Dec 5, 2035
Exclusivity Expiry
Dec 10, 2028
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 10028937 | Jun 10, 2030 | U-3238 | |
| 10039754 | Jun 10, 2030 | U-3238 | |
| 9586978 | Nov 6, 2030 | U-3238 | |
| 10039754*PED | Dec 10, 2030 | — | |
| 10028937*PED | Dec 10, 2030 | — |